Skip to main content

Table 3 Immune outcome in DPX-0907-treated patients

From: First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Total patients recruited

 

23

Full treatment received

 

22

Evaluable

 

18

Immune response (IR)

 

Positive IR in:

Breast cancer

3/3 (100%)

 

Ovarian cancer

5/6 (83%)

 

Breast/Ovarian

8/9 (89%)

 

Prostate cancer

3/9 (33%)

 

All patients

11/18 (61%)

 

Dose A

5/9 (56%)

 

Dose B

6/9 (67%)

Positive IR after:

1 vaccination

8/11 (73%)

 

2 vaccinations

2/11 (18%)

 

3 vaccinations

1/11 (9%)

Positive IR at:

1 time point

2/11 (18%)

 

2 time points

7/11 (64%)

 

3 time points

2/11 (18%)

Existing IR at:

SD73

7/11 (64%)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us